Skip to main content
SpringerLink
Log in

Systemic Lupus Erythematosus and Antiphospholipid Syndrome

  • Chapter
  • First Online:
Book cover Connective Tissue Disease

Part of the book series: Rare Diseases of the Immune System ((RDIS))

  • 1061 Accesses

Abstract

The antiphospholipid syndrome (APS) is defined by the occurrence of venous and arterial thromboses, often multiple, and recurrent fetal losses, frequently accompanied by a moderate thrombocytopenia, in the presence of antiphospholipid antibodies (aPL), namely, lupus anticoagulant (LA), anticardiolipin antibodies (aCL), or anti-β2-glycoprotein I (β2GPI) antibodies (Gómez-Puerta and Cervera, J Autoimmun 48–49:20–25, 2014). The APS can be found in patients having neither clinical nor laboratory evidence of another definable condition (primary APS), or it may be associated with other diseases, mainly systemic lupus erythematosus (SLE), but occasionally with other autoimmune conditions, infections, drugs, and malignancies.

Primary APS patients rarely progress to SLE. Only 8 % of 128 patients, who were followed up for about 9 years, developed lupus, and a positive Coombs’ test was a clinically significant predictor of progression.

The aPL can appear in different scenarios, such as asymptomatic “carrier” patients for aPL, “classical” APS with recurrent venous and/or arterial thrombosis, APS affecting otherwise healthy women with recurrent pregnancy loss, patients with aPL positivity with non-thrombotic aPL manifestations (i.e., thrombocytopenia, hemolytic anemia, or livedo reticularis), or, in a small subset of patients, as a life-threatening form characterized by a rapid development of microthrombosis that led to rapid multiorgan failure, which is termed catastrophic APS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gómez-Puerta JA, Cervera R (2014) Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun 48–49:20–25

    Article  PubMed  Google Scholar 

  2. Cervera R, Asherson RA, Acevedo ML et al (2004) Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 63:1312–1317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gómez-Puerta JA, Cervera R, Espinosa G et al (2006) Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 35:322–332

    Google Scholar 

  4. Gómez-Puerta JA, Martin H, Amigo MC et al (2005) Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine 84:225–230

    Google Scholar 

  5. Asherson RA, Bucciarelli S, Gomez-Puerta JA, Cervera R (2009) History, classification, and subsets of the antiphospholipid syndrome. In: Cervera R, Reverter JC, Khamashta MA (eds) Antiphospholipid syndrome in systemic autoimmune diseases. Elsevier, Amsterdam, pp 1–12

    Chapter  Google Scholar 

  6. Cervera R, Rodríguez-Pintó I, Espinosa G, on behalf of the Task Force on Catastrophic Antiphospholipid Syndrome (2014) Catastrophic antiphospholipid syndrome: task force report summary. Lupus 23:1283–1285

    Article  PubMed  Google Scholar 

  7. Mehrania T, Petri M (2009) Epidemiology of the antiphospholipid syndrome. In: Cervera R, Reverter JC, Khamashta MA (eds) Antiphospholipid syndrome in systemic autoimmune diseases. Elsevier, Amsterdam, pp 13–34

    Chapter  Google Scholar 

  8. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, de Jesus GR, Erkan D (2013) The estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis. Arthritis Care Res 65:1869–1873

    Article  CAS  Google Scholar 

  9. Cervera R, Espinosa G, Bucciarelli S, Gomez-Puerta JA, Font J (2006) Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmun Rev 6:81–84

    Article  PubMed  Google Scholar 

  10. Cervera R, Bucciarelli S, Plasin MA et al (2009) Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 32:240–245

    Article  CAS  PubMed  Google Scholar 

  11. Meroni PL, Borghi MO, Raschi E, Tedesco F (2011) Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7:330–339

    Article  CAS  PubMed  Google Scholar 

  12. Espinosa G, Cervera R, Font J, Shoenfeld Y (2003) Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun Rev 2:86–93

    Article  PubMed  Google Scholar 

  13. Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368:1033–1044

    Article  CAS  PubMed  Google Scholar 

  14. Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027

    Article  PubMed  Google Scholar 

  15. Cervera R, Espinosa G, Reverter JC (2009) Systemic manifestations of the antiphospholipid syndrome. In: Cervera R, Reverter JC, Khamashta MA (eds) Antiphospholipid syndrome in systemic autoimmune diseases. Elsevier, Amsterdam, pp 105–116

    Chapter  Google Scholar 

  16. Sangle SR, D’Cruz DP, Jan W et al (2003) Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis 62:999–1002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Janardhan V, Wolf PA, Kase CS et al (2004) Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 35:736–741

    Article  PubMed  Google Scholar 

  18. Khamashta MA, Cervera R, Asherson RA et al (1990) Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335:1541–1544

    Article  CAS  PubMed  Google Scholar 

  19. Pons-Estel GJ, Cervera R (2014) Renal involvement in antiphospholipid syndrome. Curr Rheumatol Rep 16:397

    Article  PubMed  Google Scholar 

  20. Gómez-Puerta JA, Pons-Estel GJ (2010) Skeletal involvement in antiphospholipid syndrome. Curr Rheumatol Rev 6:25–31

    Google Scholar 

  21. Gómez-Puerta JA, Sanin-Blair J, Galarza-Maldonado C (2009) Pregnancy and catastrophic antiphospholipid syndrome. Clin Rev Allergy Immmunol 36:85–90

    Google Scholar 

  22. Cervera R, Serrano R, Pons-Estel GJ et al (2015). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74:1011-1018

    Google Scholar 

  23. Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 74:1185–1190

    CAS  PubMed  Google Scholar 

  24. Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311

    Article  CAS  PubMed  Google Scholar 

  25. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemos 4:295–306

    Article  CAS  Google Scholar 

  26. Asherson RA, Cervera R, de Groot PG et al (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530–534

    Article  CAS  PubMed  Google Scholar 

  27. Kaul M, Erkan D, Sammaritano L, Lockshin MD (2007) Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 66:927–930

    Article  PubMed  PubMed Central  Google Scholar 

  28. Cervera R, Font J, Gomez-Puerta JA et al (2005) Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 64:1205–1209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ruffatti A, Calligaro A, Hoxha A et al (2010) Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res 62:302–307

    Article  CAS  Google Scholar 

  30. Otomo K, Atsumi T, Amengual O et al (2012) Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64:504–512

    Article  CAS  PubMed  Google Scholar 

  31. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML (2013) GAPSS: the global anti-phospholipid syndrome score. Rheumatol (Oxford) 52:1397–1403

    Article  Google Scholar 

  32. Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295:1050–1057

    Article  CAS  PubMed  Google Scholar 

  33. Coloma Bazan E, Donate Lopez C, Moreno Lozano P, Cervera R, Espinosa G (2013) Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. Immunol Res 56:358–361

    Article  CAS  PubMed  Google Scholar 

  34. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I et al (2011) Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20:206–218

    Article  CAS  PubMed  Google Scholar 

  35. Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE (2014) Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 112:947–950

    Article  PubMed  Google Scholar 

  36. Erkan D, Vega J, Ramon G, Kozora E, Lockshin MD (2013) A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 65:464–471

    Article  CAS  PubMed  Google Scholar 

  37. Berman H, Rodriguez-Pinto I, Cervera R et al (2013) Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12:1085–1090

    Article  CAS  PubMed  Google Scholar 

  38. Shapira I, Andrade D, Allen SL, Salmon JE (2012) Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 64:2719–2723

    Article  CAS  PubMed  Google Scholar 

  39. Canaud G, Kamar N, Anglicheau D et al (2013) Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 13:2179–2185

    Article  CAS  PubMed  Google Scholar 

  40. Alarcon-Segovia D, Boffa MC, Branch W et al (2003) Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 12:499–503

    Article  CAS  PubMed  Google Scholar 

  41. Erkan D, Harrison MJ, Levy R et al (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56:2382–2391

    Article  CAS  PubMed  Google Scholar 

  42. Tincani A, Branch W, Levy RA et al (2003) Treatment of pregnant patients with antiphospholipid syndrome. Lupus 12:524–529

    Article  CAS  PubMed  Google Scholar 

  43. Carmona F, Font J, Azulay M et al (2001) Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 46:274–279

    Article  CAS  PubMed  Google Scholar 

  44. Cervera R, Balasch J (2004) The management of pregnant patients with antiphospholipid syndrome. Lupus 13:683–687

    Article  CAS  PubMed  Google Scholar 

  45. Gomez-Puerta JA, Cervera R (2013) Are there additional options for the treatment of refractory obstetric antiphospholipid syndrome? Lupus 22:754–755

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Grupo de Inmunología Celular e Inmunogenética (GICIG), and Sección de Reumatología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia

    Jose A. Gómez-Puerta

  2. Department of Autoimmune Diseases, Hospital Clinic, Villarroel, 170, Barcelona, Catalonia, 08036, Spain

    Ricard Cervera

Authors
  1. Jose A. Gómez-Puerta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ricard Cervera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jose A. Gómez-Puerta .

Editor information

Editors and Affiliations

  1. Giovanni Bosco Hospital, Center of Immunopathology/Rare Dise, Torino, Torino, Italy

    Dario Roccatello

  2. University of Florence, Florence, Italy

    Lorenzo Emmi

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Gómez-Puerta, J.A., Cervera, R. (2016). Systemic Lupus Erythematosus and Antiphospholipid Syndrome. In: Roccatello, D., Emmi, L. (eds) Connective Tissue Disease. Rare Diseases of the Immune System. Springer, Cham. https://doi.org/10.1007/978-3-319-24535-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-24535-5_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-24533-1

  • Online ISBN: 978-3-319-24535-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation